Docket No. 13720-105074US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	(s): Jacob Waugh et al.	Confirmation No:	1919		
Serial No.	: 10/591,485	Group Art Unit:	1656		
Filed:	November 7, 2007	Examiner:	Samuel W. Liu		
For:	Multi-Component Biological	Transport Systems			
P.O. Box	oner for Patents 1450 a, VA 22313-1450				
	SUPPLEMENTAL INFORMAT	TION DISCLOSURE S	<u>TATEMENT</u>		
Sir:					
	This Information Disclosure Sta	atement is filed in accord	lance with 37 C.F.R.		
§§1.56, 1.	97 and 1.98. The items listed on For	m PTO-SB08, a copy of	which is enclosed, are		
made of re	ecord to assist the Patent and Tradem	ark Office in its examina	ation of this application.		
The Exam	iner is respectfully requested to fully	consider the items and	to independently ascertain		
their teach	ning.				
1.	For each of the following items listed on the enclosed copy of Form PTO-SB08 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:				
2.	For each of the following items listed on the enclosed copy of Form PTO-SB08 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.				
3.	Any copy of the items listed on the enclosed copy of Form PTO-SB08 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No, filed				
	<u> </u>				
4. 🛛	No fee is due under 37 C.F.R. §1.17 since it is being filed in compliance	Disclosure Statement			
	37 C.F.R. §1.97(b)(1), within application other than a CPA		ng date of a national		
	37 C.F.R. §1.97(b)(2), within national stage as set forth in		-		

		\boxtimes	37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or	
			37 C.F.R. §1.97(b)(4) before the mailing date of a first office action after the filing of an RCE under §1.114.	
5.		No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specific in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.		
6.		it is be parage	is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since eing filed in compliance with 37 C.F.R. §1.97(c), after the period specified in raph 4 above but before the mailing date of a final action or a notice of ance (where there has been no prior final action):	
			A check in the amount of \$180.00 is enclosed in payment of the fee.	
			Charge the fee to Deposit Account No. <u>50-3732</u> , Order No	
7.		A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, whichever comes first, but before payment of the issue fee, and is accompanied by:		
			ne of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 elow; and	
			te fee due under 37 C.F.R. §1.17(p) which is paid as set forth in paragraph 11 elow.	
8.		This I	nformation Disclosure Statement is being filed in compliance with:	
		a. 🗌	37 C.F.R. §1.313(b)(3) or §1.313(c)(1), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h);	
		b	37 C.F.R. §1.313(c)(2) or §1.313(c)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Request for Continued Examination (RCE) or a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h).	
		c. 🗌	The fee due under 37 C.F.R. §§1.17(h) is paid as set forth in paragraph 11 below.	
9.			by certify that each item of information contained in this Information Disclosure nent was first cited in a communication from a foreign patent office in a	

	counterpart foreign application not mo Information Disclosure Statement.	re than three months prior to the filing of this			
	filed herewith was cited in a communi counterpart foreign application or, to n	ation in the Information Disclosure Statement cation from a foreign patent office in a my knowledge after making reasonable inquiry, and in §1.56(c) more than three months prior to be Statement.			
10.	This document is accompanied by a Search Report Communication which was cited in a corresponding PCT or Foreign counterpart application.				
11.	A check in the amount of \$ is en C.F.R. §§1.17(h) and 1.17(p).	closed in payment of the fees due under 37			
	Charge any fees due under 37 C.F.R. § 50-3732, Order No	§1.17(h) and 1.17(p) to Deposit Account No.			
\boxtimes	The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-3732, Order No. 13720-105074.				
		Respectfully submitted, KING & SPALDING LLP			
Dated: October 5, 2010 By:		Joseph D. Eng Jr.			
		Joseph D. Eng, Jr. Reg. No. 54,084			
Correspondence Address:					
King & Spalding LLP					
1185 Avenue of the Americas					
ALAYYY MAN					

New York, NY 10036 212-556-2100 Telephone 212-556-2222 Facsimile